Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma.
Junichi ShindohYusuke KawamuraMasahiro KobayashiNorio AkutaSatoshi OkuboMasaru MatsumuraYoshiyuki SuzukiMasaji HashimotoPublished in: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2022)
Additional intervention(s)/treatment(s) after lenvatinib therapy for advanced HCC may have prognostic advantage in strictly selected populations. Successful conversion to curative resection may offer survival benefit with acceptable clinical outcomes.